April 3, 2008 . A team of researchers from the University of Sunderland and bioMérieux, a leading company in the field of in vitro diagnostics, have achieved a new step in the fight against Pseudomonas aeruginosa, a bacterium responsible for deadly healthcare-associated infections, which kills tens of thousands of people throughout the world every year .
Researchers at the University of Sunderland’s Pharmacy School, Professor Paul Groundwater and Dr. Roz Anderson, in collaboration with Prof. John Perry of Freeman Hospital in Newcastle, Prof. Arthur James of Northumbria University and Sylvain Orenga of bioMérieux have discovered a new technique for the highly specific detection of Pseudomonas aeruginosa, which primarily infects the lungs of patients with cystic fibrosis. It is also a major cause of infection among patients with immune deficiencies, such as patients with AIDS and cancer or those suffering from burns... bioMérieux's Press Release - Communiqué de Presse de BioMérieux -
Blog Archive
-
▼
2008
(66)
-
▼
April
(10)
- Hybrigenics : Significant progress in cancer-relat...
- GENFIT : encouraging results in GFT505 first clini...
- Diatos : Pre-Clinical Results in Clinical Cancer R...
- BioAlliance Pharma Expands Its Loramyc Franchise
- PerkinElmer and Cerep : Partners for Custom Drug D...
- bioMerieux : Collaboration with University of Sun...
- GenOdyssee : Notice of Allowance from U.S. Patent ...
- LDR : Two-Level Cervical Disc Study Enrollment in ...
- MacoPharma : THERAFLEX Methylene Blue (MB)-Plasma
- genOway : Master service agreement with Boehringer...
-
▼
April
(10)